Lisa P. Young Appointed to Valo’s Board of Directors

BOSTON, Jan­u­ary 4, 2024 /​PRNewswire/​– Valo Health, Inc (“Valo”), a tech­nol­o­gy com­pa­ny focused on uti­liz­ing large scale data and arti­fi­cial intel­li­gence (“AI”) dri­ven com­pu­ta­tion to dis­cov­er and devel­op ther­a­peu­tics, today announced the appoint­ment of Lisa P. Young to its Board of Direc­tors and as the chair of its Audit Com­mit­tee. Young is a sea­soned board mem­ber and glob­al busi­ness leader with over 36 years of cross-sec­tor, inter­na­tion­al expe­ri­ence in pub­lic account­ing and pro­fes­sion­al services.

“I am hon­ored to wel­come Lisa to the Valo Board of Direc­tors. Her near­ly four decades at EY in work­ing with new busi­ness mod­els and tech­nol­o­gy lead­ers across mul­ti­ple indus­tries have armed her with the exper­tise to exceed in lead­ing our Board’s audit com­mit­tee,” said Valo CEO and Founder, David Berry, PhD, MD. ​“Lisa brings a dis­tinc­tive skillset and shares in our phi­los­o­phy that suc­cess starts with cul­ture. I am excit­ed to part­ner with Lisa as we build the next phase of Valo.”

“I am thrilled to join Valo Health’s board of direc­tors and to chair its audit com­mit­tee,” said Young. ​“I am inspired by Valo’s mis­sion to devel­op bet­ter ther­a­peu­tics for patients faster using large scale human-cen­tric data, and by the team that has come togeth­er to bring this excit­ing vision to real­i­ty. I look for­ward to apply­ing what I’ve learned through­out my career to com­ple­ment the orga­ni­za­tion to future successes.”

Young was with Ernst & Young LLP (“EY”) for 36 years, with 24 of those years as a part­ner, and held sev­er­al busi­ness lead­er­ship and client serv­ing roles includ­ing Senior Glob­al Client Ser­vice Part­ner, Amer­i­c­as Pro­fes­sion­al Prac­tice Part­ner and Glob­al Cap­i­tal Mar­kets Part­ner in EY’s nation­al office. Young serves on the Board of Direc­tors of Accelus, Inc., a com­pa­ny focused on min­i­mal­ly inva­sive spine surgery tech­nol­o­gy, and chairs their audit and finance com­mit­tee and is a mem­ber of the nom­i­nat­ing and cor­po­rate gov­er­nance com­mit­tee, and on the Board of Direc­tors of Tex­tain­er Group Hold­ings (NYSE: TGH) as a direc­tor and mem­ber of their audit and risk com­mit­tee and the com­pen­sa­tion com­mit­tee. She serves as the Advance­ment Chair of the Board of Trustees for the Colum­bus Muse­um of Art, a mem­ber and Finance Chair of the Board of Direc­tors of the Dal­las Black Dance The­atre and for FringeArts in Philadel­phia, and a mem­ber of the Texas Tech Uni­ver­si­ty Rawls Col­lege of Busi­ness Advi­so­ry Coun­cil. Young holds a Bach­e­lor of Busi­ness Admin­is­tra­tion, Cum Laude, in Finance and Account­ing from Texas Tech Uni­ver­si­ty, and is a cer­ti­fied pub­lic accountant.

About Valo Health
Valo Health, Inc is a tech­nol­o­gy com­pa­ny focused on uti­liz­ing large scale data and AI-dri­ven com­pu­ta­tion to dis­cov­er and devel­op ther­a­peu­tics. Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life cycle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing costs, time, and fail­ure rates. The company’s Opal Com­pu­ta­tion­al Plat­form™ is an end-to-end drug dis­cov­ery and devel­op­ment plat­form with a uni­fied archi­tec­ture designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams, ini­tial­ly focused on car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in Lex­ing­ton, MA, and New York, NY. To learn more, vis­it val​o​health​.com.

Con­tacts
Investors: Graeme Bell, Chief Finan­cial Offi­cer, gbell@​valohealth.​com
Media: Kate Clay­ton, Cor­po­rate Com­mu­ni­ca­tions, kclayton@​valohealth.​com